Perspective Therapeutics, Inc. (CATX) Misses Q2 EPS by 16c

Perspective Therapeutics, Inc. (NYSE: CATX) reported Q2 EPS of ($0.18), $0.16 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $87.75 thousand.

For earnings history and earnings-related data on Perspective Therapeutics, Inc. (CATX) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Lobe Sciences closes $2.16M private placement for S-100 drug program